ArticleAnnals of surgical oncology2026
Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the USA: A Multicenter Real-World Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDe novo metastatic breast cancer-defined by distant metastases at diagnosis-poses treatment challenges. While systemic therapy is standard, the benefit of primary tumor surgery remains debated. This study compared surgical patterns and survival in China versus the USA to provide evidence for personalized strategies. PATIENTS AND
methodsIn this multicenter retrospective cohort study, patients with surgically treated de novo metastatic breast cancer were identified from the National Cancer Center Oncology Information Database (NCCOID; n = 2037, 2013-2020) and Surveillance, Epidemiology, and End Results (SEER) (n = 3175, 2013-2020). Clinical features, treatments, and overall survival (OS) were contrasted. Kaplan-Meier curves and multivariable Cox models identified OS predictors.
resultsCompared with SEER, NCCOID patients were younger and had more T2 tumors; mastectomy predominated in both, though breast-conserving surgery was more frequent in SEER, and preoperative systemic therapy was more common in NCCOID. NCCOID achieved superior OS (1 year, 3 year, 5 year: 91.5%, 77.4%, 67.9%, respectively) versus SEER (87.7%, 62.8%, 46.4%). Improved survival was seen in hormone-receptor-positive tumors, smaller primary lesions (lower T category), and bone-only metastases. Multivariate analysis confirmed age 35-54 years, HR+ and HER2+ status, and limited (especially bone-only) metastases as independent favorable factors.
conclusionsSurgical management of de novo metastatic breast cancer differs between China and the USA. Select patients-particularly those with HR+ or HER2+ tumors, small primaries, and limited metastases-may benefit from resection, underscoring the need for multidisciplinary, personalized decision-making and prospective validation of optimal surgical timing.
Indexed as
Identifiers
41073822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.